Medicilon : Writing

Routes of Drug Administration Platform

Routes of Drug Administration Platform

A Story by Medicilon


Drug administration route is often classified by the location at which the drug is administered, such as oral or intravenous. The choice of routes in ..
Continuous Flow Chemical Technology

Continuous Flow Chemical Technology

A Story by Medicilon


The continuous flow chemistry technology service platform is one of the important technologies used by Medicilon to support green chemistry. Based on ..
STAT3-targeted Drugs R&D Service

STAT3-targeted Drugs R&D Service

A Story by Medicilon


STAT3, a member of the STAT family, is a latent transcription factor that is activated in response to various cytokines, growth factors, and oncogene ..
KRAS-targeted Drugs R&D Service

KRAS-targeted Drugs R&D Service

A Story by Medicilon


RAS is one of the most frequently mutated oncogenes in human cancer. KRAS is the isoform most frequently mutated, which constitutes about 85% of RAS m..
Medicilon was selected as "2023 Science and Technology Innovation Board Hard and Core Technology Lea

Medicilon was selected as "2023 Science and Techno..

A Story by Medicilon


On September 27, the "STAR Summit" was grandly held in Shanghai. The Summit announced the selection list for the fourth anniversary of science and te..
Peptide Synthesis

Peptide Synthesis

A Story by Medicilon


The Medicilon peptide synthesis research team closely focuses on the theme of peptide drug research and is committed to solving the core issues that l..
Drug Solid-State Research Service Platform

Drug Solid-State Research Service Platform

A Story by Medicilon


Medicilon's pharmaceutical solid-state research service platform is dedicated to crystal form research services in the development of new drugs and ge..
Anti-drug Antibody Preparation

Anti-drug Antibody Preparation

A Story by Medicilon


Medicilon has rich experience in ADA development and has successfully delivered more than 100 projects. Medicilon can provide high-affinity and specif..
Medicilon Assists ABM Therapeutics to Obtain US FDA Orphan Drug Qualification for ABM-1310 for the T

Medicilon Assists ABM Therapeutics to Obtain US FD..

A Story by Medicilon


Shanghai, China/San Diego,USA - August 2, 2023, ABM Therapeutics announced that its self-developed small molecule BRAF inhibitor ABM-1310 has obtained..
Botanical Drug Preclinical R&D Technology Platform

Botanical Drug Preclinical R&D Technology Platform

A Story by Medicilon


Medicilon Botanical Drug Preclinical R&D Technology Service Platform is established based on the existing drug pharmacokinetic and safety evaluation r..